Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Amgen, Inc. (AMGN) vs. Big Pharma: It’s Amgen for the Long Term

The stock has responded well, up over 40% during the period.  Still the market clearly expects slower growth from Amgen, Inc. (NASDAQ:AMGN) compared to the other biotech companies and is pricing the stock below even some big pharmaceutical companies based on its discounted price/earnings ratio.

Compared to big pharma AMGN boasts solid earnings growth at a deep discount

One of the most attractively priced large-cap pharmaceuticals, Merck & Co., Inc. (NYSE:MRK) yields 3.7% and trades at a slight price/earnings ratio premium to Amgen at 13 times 2014 earnings. The company boasts a robust pipeline and the stock received a big boost from the presentation of strong early-stage clinical trial results  for lambrolizumab at the American Society of Clinical Oncology meeting earlier this month. Lambrolizumab is a checkpoint inhibitor that blocks cancer cells from hiding from the body’s immune system. The company may file for regulatory approval in 2015 and the drug clearly contains blockbuster potential.  As is often the case, investors rewarded the stock with a 10% move initially, but it has since drifted down to pre-announcement levels. The pipeline is exciting but the stock lacks short-term catalysts and is expected to grow earnings in the low-single digits over the next 12 months. Bristol Myers Squibb Co. (NYSE:BMY) also announced strong early-stage clinical trial results for a drug similar to Merck & Co., Inc. (NYSE:MRK)’s that harnesses the immune system to kill cancer cells. The segment is red hot to be sure. Bristol Myers Squibb Co. (NYSE:BMY) is expected to post strong earnings growth of 17.6% in the coming year and boasts a yield of around 3%.  But the stock is trading at 21.1 times 2014 earnings — a premium to the market and peer group. The good news seems priced into the stock in the near term.

The bottom line

Amgen’s Bradway is rationalizing the business and has targeted $1 billion in operating efficiencies by 2015. Though 82% of sales are concentrated in five drugs, the company has created a new blockbuster franchise in osteoporosis treatments that is expected to double to $3 billion in sales. Management’s commitment to returning value to the shareholder through dividend growth and stock buybacks of 60% of adjusted net income is also noteworthy. The stock carries an attractive valuation and expected earnings growth of 12% in the next year. Add to that a promising pipeline with late-stage data on new treatments for psoriasis and cholesterol expected by 2016 and you likely have a stock that complies with Intelligent Investing Rule #1.

I’ve said it before and I’ll say it again: Buy great companies for the long-term.

Nancy Tengler owns AMGN. The Motley Fool has no position in any of the stocks mentioned. Nancy is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

The article Amgen vs. Big Pharma: It’s Amgen for the Long Term originally appeared on is written by Nancy Tengler.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.